Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02726711 · ClinicalTrials.gov registry record · Phase 1

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic

A Phase 1 study of Multiple System Atrophy and Orthostatic Hypotension, sponsored by Vanderbilt University.

Active
Registry status
Phase 1
Development phase
2
Enrollment target
1
Study location

NCT02726711: Active Phase 1 study of Multiple System Atrophy and Orthostatic Hypotension, sponsored by Vanderbilt University.

NCT02726711 is a Phase 1 study of Multiple System Atrophy and Orthostatic Hypotension that is active but no longer recruiting, run by Vanderbilt University. The registered enrollment target is 2 participants, below the 268-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02726711, a Phase 1 study of Multiple System Atrophy and Orthostatic Hypotension, is active but no longer recruiting, sponsored by Vanderbilt University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
2 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn more about the regulation of the veins of the abdomen by the autonomic (involuntary) nervous system, and how this may affect high blood pressure. Normally, the autonomic nervous system controls how much blood flows in the veins. In people with high blood pressure, however, the autonomic nervous system is changed. This change may affect the way blood flows in the veins of the abdomen which may play a role in their high blood pressure. About 32 participants will be screened for the study. The investigators estimate 16 will be eligible to participate in all of the study days.

Primary Outcome

To determine whether autonomic blockade with trimethaphan increases splanchnic capacitance (parallel upward shift in the P-V relationship) compared to placebo.

Interventions

  • DRUG Placebo
  • DRUG Trimethaphan

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2016-04
Est. Completion 2026-12
Phase Phase 1
Vanderbilt University

430 total trials

What the registry record for NCT02726711 still lists

NCT02726711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 268-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Multiple System Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02726711 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT02726711 about?

NCT02726711 is a clinical study titled "Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic". The purpose of this study is to learn more about the regulation of the veins of the abdomen by the autonomic (involuntary) nervous system, and how this may affect high blood pressure. Normally, the autonomic nervous system controls how much blood flows in the veins. In people with high blood pressur...

What is the current status of trial NCT02726711?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-04. Estimated completion is 2026-12.

What conditions does trial NCT02726711 study?

This clinical trial studies the following conditions: Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension.

What interventions are being tested in trial NCT02726711?

The interventions under investigation include: Placebo (DRUG), Trimethaphan (DRUG).

Who is sponsoring clinical trial NCT02726711?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02726711 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple System Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02726711's enrollment target sits among peer trials

2 31st of 30 the lowest of 30 other Multiple System Atrophy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple System Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02726711, the US trial registry maintained by the National Library of Medicine. NCT02726711 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.